Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 12:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 359 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Irritable Colon Clear all
Completed Phase 2 Interventional Results available

Citalopram in Irritable Bowel Syndrome

NCT00477165
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Citalopram, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 24, 2026, 12:21 PM EDT
Completed Not applicable Interventional Results available

Does Improving Vagal Tone Increase Mitochondrial Bioenergetics

NCT03931330
View directory record Official record
Conditions
Functional Gastrointestinal Disorders, Irritable Bowel Syndrome, Dyspepsia, Functional Abdominal Pain Syndrome
Interventions
Percutaneous neurostimulation
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
12 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 24, 2026, 12:21 PM EDT
Not listed Phase 2 Interventional

Acupuncture/Moxibustion for Irritable Bowel Syndrome (IBS)

NCT00945074
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Standard Acupuncture/Moxibustion (fixed protocol), Individualized Acupuncture/Moxibustion, Sham/Placebo Acupuncture/Moxibustion
Other
Lead sponsor
New York University
Other
Eligibility
18 Years to 70 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 24, 2026, 12:21 PM EDT
Completed Phase 2 Interventional

Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)

NCT00101985
View directory record Official record
Conditions
Irritable Colon
Interventions
talnetant
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
70
States / cities
Chandler, Arizona • Phoenix, Arizona • North Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 24, 2026, 12:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

NCT03555617
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
TD-1473, Itraconazole
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 24, 2026, 12:21 PM EDT
Completed Not applicable Interventional Results available

Mindfulness-Based Stress Reduction for Bowel Symptoms: Collection of Pilot Survey Data

NCT00880256
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
mindfulness-based stress reduction
Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 24, 2026, 12:21 PM EDT
Completed Phase 2 Interventional Results available

A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C

NCT02493036
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
SYN-010
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
11
States / cities
Hialeah, Florida • Miami, Florida • Miami Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 24, 2026, 12:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Correlation Between Central Sensitization Inventory and Posturographic Data

NCT03058003
View directory record Official record
Conditions
Central Nervous System Sensitization
Interventions
Posturography Evaluation, Central Sensitization Inventory
Diagnostic Test · Other
Lead sponsor
Caps Research Network
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 12:21 PM EDT
Completed Not applicable Interventional

Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients

NCT03550742
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
Fuco-N-Tetraose
Other
Lead sponsor
Glycom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 24, 2026, 12:21 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 24, 2026, 12:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

GutMe!: IBS and Collagen Protein Powder an Interventional Study

NCT04245254
View directory record Official record
Conditions
Irritable Bowel Syndrome, Irritable Bowel, Irrit
Interventions
Collagen Protien Powder
Dietary Supplement
Lead sponsor
ProofPilot
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 24, 2026, 12:21 PM EDT
Withdrawn Phase 3 Interventional

Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea

NCT04612803
View directory record Official record
Conditions
Irritable Bowel Syndrome, Dermatographism, Post-prandial Diarrhea
Interventions
Antihistamine, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 24, 2026, 12:21 PM EDT
Completed Phase 2 Interventional Results available

SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation

NCT01053962
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
SP-304 0.3 mg, SP-304 1.0 mg, SP-304 3.0 mg, SP-304 9.0 mg, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
14
States / cities
Mesa, Arizona • Tucson, Arizona • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 24, 2026, 12:21 PM EDT
Terminated Phase 1 Interventional

Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome

NCT00316550
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
AV608
Drug
Lead sponsor
Avera Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2008 · Synced Oct 24, 2026, 12:21 PM EDT
Completed Not applicable Interventional Results available

Acceptability and Efficacy of the Zemedy App for Irritable Bowel Syndrome

NCT04170686
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Zemedy App for Irritable Bowel Syndrome
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 24, 2026, 12:21 PM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01887002
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
ONO-2952, Placebo comparator
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Oct 24, 2026, 12:21 PM EDT
Recruiting Not applicable Interventional

Feasibility Study of a Guided Imagery Therapy Mobile Application for Functional Abdominal Pain Disorders in Children

NCT07222943
View directory record Official record
Conditions
Functional Abdominal Pain Disorders, Irritable Bowel Syndrome (IBS), Functional Gastrointestinal Disorders (FGIDs), Gastrointestinal and Digestive Disorder, Abdominal Pain/ Discomfort, Pain, Functional Dyspepsia
Interventions
Guided Imagery Therapy
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 12 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Austin, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 24, 2026, 12:21 PM EDT
Completed Not applicable Interventional

RCT of VR Therapy for IBS

NCT06687616
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
SynerGI, Sham VR
Device
Lead sponsor
Christopher Almario
Other
Eligibility
10 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Los Angeles, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 24, 2026, 12:21 PM EDT
Completed Not applicable Interventional

Effects of Relaxation Response Mind-body Intervention in Patients With IBS and IBD

NCT02136745
View directory record Official record
Conditions
Irritable Bowel Syndrome, Inflammatory Bowel Disease
Interventions
Relaxation Response Mind-Body Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 24, 2026, 12:21 PM EDT
Completed Not applicable Interventional

Telehealth-Delivered Gut-Directed Hypnotherapy for Managing GI Health

NCT06890663
View directory record Official record
Conditions
Gastrointestinal Disease, Gastrointestinal Disorders, Nervous System
Interventions
Nonspecific Hypnotherapy for Relaxation, Gut-Directed Hypnotherapy (GDH), 3-month Follow-Up
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 24, 2026, 12:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)

NCT01072903
View directory record Official record
Conditions
Inflammation, Colon, Irritable, Colonic Diseases, Functional, Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Oct 24, 2026, 12:21 PM EDT
Completed Phase 2 Interventional Results available

Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome

NCT01786109
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Michael Camilleri
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 24, 2026, 12:21 PM EDT
Terminated Phase 3 Interventional

Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

NCT00607971
View directory record Official record
Conditions
Constipation-Predominant Irritable Bowel Syndrome
Interventions
Renzapride
Drug
Lead sponsor
Alizyme
Industry
Eligibility
18 Years and older · Female only
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
126
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 112 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2008 · Synced Oct 24, 2026, 12:21 PM EDT
Completed Not applicable Interventional Results available

The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation

NCT03054506
View directory record Official record
Conditions
Constipation, Chronic Idiopathic Constipation, Irritable Bowel Syndrome With Constipation
Interventions
CSP01, Carboxymethylcellulose (CMC), Placebo
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
22 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 24, 2026, 12:21 PM EDT